Innate Pharma publishes presentation for May 21, 2026 extraordinary shareholder meeting

• Innate Pharma published a shareholder meeting presentation outlining resolutions that would renew board authority to raise equity to support operations and potential external growth.
• A proposed global issuance cap of EUR 9.39 million in nominal amount would apply across several capital increase authorizations, including issuances with pre-emptive rights or via public offering, private placement, or reserved allocations; each framework also allows up to EUR 150 million in nominal amount of debt securities giving access to capital.
• Pricing floors include a five-session volume-weighted average with a maximum 15% discount for public offers, private placements, or reserved categories; a separate named-investor issuance allows up to a 10% discount to the prior close.
• A separate resolution would allow a 15% upsize option within 30 days of subscription close for capital increases carried out under those delegations.
• Other votes cover share-based incentives, including performance share grants of up to 1,125,000 shares for executives and directors, 1,500,000 shares for employees, additional free share grants of up to 150,000 shares for executives and directors, 500,000 shares for employees, a EUR 15,000 employee share plan issuance, up to 60,000 shares via standalone warrants for directors or consultants, and authority to cancel up to 10% of treasury shares over 24 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.